Endocrinology

Top Story

FDA advisory panel recommends approval for Sanofi-Aventis’ iGlarLixi combination drug

May 25, 2016

WASHINGTON — An FDA advisory panel has recommended approval of Sanofi-Aventis’ new drug application 208673 for insulin glargine and lixisenatide injection, to be known as IGlarLixi, for treatment of patients with type 2 diabetes.

The Endocrinologic and Metabolic Drugs Advisory Committee voted 12-2 in favor of recommending approval of iGlarLixi, a titratable fixed-ratio combination of basal insulin glargine 100 U/mL (Lantus) and lixisenatide, a glucagon-like peptide-1 receptor agonist.

Meeting News CoverageVideo

VIDEO: Select patients may benefit from bisphosphonate holidays

May 25, 2016
ORLANDO, Fla. — In this video, AACE President Pauline Camacho, MD, FACE, discusses her approach to osteoporosis management. Rare medication side effects are…
Meeting News Coverage

Transculturalization initiative addresses diverse needs in Latin American patient care

May 25, 2016
ORLANDO, Fla. — New recommendations spearheaded by the American Association of Endocrinologists and the American College of Endocrinology will help bridge the…
Meeting News Coverage

AACE unveils new clinical practice guideline for obesity management

May 25, 2016
ORLANDO, Fla. — A patient-centric approach to obesity management that individualizes treatment and focuses on overall health — not just weight loss —…
Meeting News Coverage

AACE/ACE app offers clinical guidance for management of type 2 diabetes

May 25, 2016
ORLANDO, Fla. —The American Association of Clinical Endocrinologists and the American College of Endocrinology announced the worldwide availability of an in-depth…
More News Headlines »
CME

Managing Obesity in 2015: Setting the Framework and Assessing All of the Options

This activity is supported by an educational grant from Novo Nordisk.

This CME activity is based on the slides and lectures presented by the faculty at the symposium, Managing Obesity in…
More »
Video
Meeting News Coverage

VIDEO: Breaks in sitting time reduce cardiometabolic risk factors in type 2 diabetes

May 4, 2016
More »
Featured
Highlights from AACE

Highlights from AACE

CME Video

Managing Today's EP Challenges with NOAC Use

This activity is supported by independent educational grants from Boehringer Ingelheim Pharmaceuticals, Inc. and Daiichi Sankyo, Inc.

This engaging activity featuring a superb faculty provides electrophysiologists and others with the best information…
More »
Current Issues
View the Current Issues
morganatic-roan
morganatic-roan